Sugi Predict

Sugi Predict / Compounds / SCHEMBL10610491

SCHEMBL10610491

SCHEMBL10610491

COc1ccc(C2Oc3cc(O)cc(O)c3C(=O)C2OC(C)=O)cc1O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.67
▸ KMT2A Q03164 4/20 0.67
▸ CYP3A4 P08684 6/20 0.56
▸ MAPT P10636 5/20 0.56
▸ CYP2C9 P11712 5/20 0.56
▸ HSD17B10 Q99714 4/20 0.56
▸ XDH P47989 3/20 0.56
▸ TP53 P04637 3/20 0.56
▸ HIF1A Q16665 3/20 0.56
▸ HPGD P15428 3/20 0.56
▸ ALDH1A1 P00352 3/20 0.56
▸ CYP19A1 P11511 2/20 0.56
▸ CYP1A2 P05177 2/20 0.56
▸ MAPK1 P28482 2/20 0.56
▸ TSHR P16473 2/20 0.56
▸ CYP2C19 P33261 2/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ PKM P14618 1/20 0.56
▸ NPC1 O15118 1/20 0.56
▸ CA12 O43570 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23085410 1.00 MEN1 (0.67) MEN1KMT2ACYP3A4MAPTCYP2C9
SCHEMBL30080341 0.89 MEN1 (0.66) MEN1KMT2ACYP3A4MAPTCYP2C9
SCHEMBL1245779 0.89 MEN1 (0.66) MEN1KMT2ACYP3A4MAPTCYP2C9
SCHEMBL2119758 0.89 MEN1 (0.66) MEN1KMT2ACYP3A4MAPTCYP2C9
SCHEMBL29378078 0.89 MEN1 (0.66) MEN1KMT2ACYP3A4MAPTCYP2C9
3,4'-O-Dimethylquercetin SCHEMBL25437986 0.89 CYP3A4 (0.60) MEN1KMT2ACYP3A4MAPTCYP2C9
3,4'-O-Dimethylquercetin SCHEMBL25437988 0.89 CYP3A4 (0.60) MEN1KMT2ACYP3A4MAPTCYP2C9
SCHEMBL31088169 0.88 MEN1 (0.59) MEN1KMT2ACYP3A4MAPTCYP2C9
SCHEMBL14894756 0.87 MEN1 (0.71) MEN1KMT2ACYP3A4MAPTCYP2C9
SCHEMBL23085395 0.87 MEN1 (0.65) MEN1KMT2ACYP3A4MAPTCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2770843-B1 SWEETNESS ENHANCING COMPOSITION COMPRISING STEVIOSIDE AND REBAUDIOSIDE A GIVAUDAN SA (CH) 2017-08-09 — — EP claimed
US-20140370177-A1 COMPOSITIONS GIVAUDAN S.A. (CH) 2014-12-18 — — US claimed
EP-2770843-A1 COMPOSITIONS Givaudan SA (CH) 2014-09-03 — — EP claimed
WO-2013060746-A1 COMPOSITIONS GIVAUDAN SA (CH) 2013-05-02 — — WO claimed
US-20240197604-A1 COMPOUNDS WITH COOLING SENSATION PROPERTIES GIVAUDAN SA (CH) 2024-06-20 — — US disclosed
US-20240165004-A1 ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2024-05-23 — — US disclosed
US-20240139087-A1 ORGANIC COMPOUNDS AS TRPM8 ACTIVATORS GIVAUDAN SA (CH) 2024-05-02 — — US disclosed
US-20240132487-A1 SUBSTITUTED AZACYLES AS TRMP8 MODULATORS GIVAUDAN SA (CH) 2024-04-25 — — US disclosed
US-20240108562-A1 FLAVOUR COMPOSITIONS GIVAUDAN SA (CH) 2024-04-04 — — US disclosed
CN-116867775-A Organic compounds as TRPM8 activators 奇华顿股份有限公司 2023-10-10 — — CN disclosed
US-20230310293-A1 COOLING SENSATION COMPOSITIONS GIVAUDAN SA (CH) 2023-10-05 — — US disclosed
US-20230277427-A1 COOLING SENSATION COMPOSITIONS GIVAUDAN SA (CH) 2023-09-07 — — US disclosed
EP-2770843-B1 SWEETNESS ENHANCING COMPOSITION COMPRISING STEVIOSIDE AND REBAUDIOSIDE A GIVAUDAN SA (CH) 2017-08-09 — — EP disclosed
US-9259027-B2 Sweetened beverages GIVAUDAN S.A. (CH) 2016-02-16 — — US disclosed
EP-2793621-B1 SWEETENED BEVERAGES GIVAUDAN SA (CH) 2015-10-14 — — EP disclosed
US-20140370177-A1 COMPOSITIONS GIVAUDAN S.A. (CH) 2014-12-18 — — US disclosed
US-20140342078-A1 SWEETENED BEVERAGES GIVAUDAN S.A. (CH) 2014-11-20 — — US disclosed
EP-2770843-A1 COMPOSITIONS Givaudan SA (CH) 2014-09-03 — — EP disclosed
WO-2013060746-A1 COMPOSITIONS GIVAUDAN SA (CH) 2013-05-02 — — WO disclosed
WO-1988008256-A1 DIHYDROFLAVONOL DERIVATIVES USEFUL AS SWEETENERS UNIVERSITY PATENTS, INC. (US) 1988-11-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230277427-A1 COOLING SENSATION COMPOSITIONS TRPA1, TRPV1, TRPV5 MEN1 1862/4885KMT2A 3917/4885CYP3A4 1647/4885
US-20240165004-A1 ORGANIC COMPOUNDS TAS2R8, TAS2R10, TAS2R20 MEN1 3178/4885KMT2A 2058/4885CYP3A4 493/4885
US-20240108562-A1 FLAVOUR COMPOSITIONS TAS2R9, TAS2R19, TAS2R16 MEN1 4457/4885KMT2A 3749/4885CYP3A4 2080/4885
US-20240132487-A1 SUBSTITUTED AZACYLES AS TRMP8 MODULATORS TRPM8, TRPM7, TRPM5 MEN1 3357/4885KMT2A 741/4885CYP3A4 1746/4885
US-20240197604-A1 COMPOUNDS WITH COOLING SENSATION PROPERTIES TRPM8, TRPM4, TRPM7 MEN1 1703/4885KMT2A 3610/4885CYP3A4 2388/4885
US-20240139087-A1 ORGANIC COMPOUNDS AS TRPM8 ACTIVATORS TRPM8, TRPM7, TRPM4 MEN1 1788/4885KMT2A 2601/4885CYP3A4 1040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback